Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

Expression of Cannabinoid Receptors in Human Osteoarthritic Cartilage: Implications for Future Therapies.

Dunn SL, Wilkinson JM, Crawford A, Bunning RAD, Le Maitre CL.

Cannabis Cannabinoid Res. 2016 Jan 1;1(1):3-15. doi: 10.1089/can.2015.0001. eCollection 2016.

2.

An Overview on Medicinal Chemistry of Synthetic and Natural Derivatives of Cannabidiol.

Morales P, Reggio PH, Jagerovic N.

Front Pharmacol. 2017 Jun 28;8:422. doi: 10.3389/fphar.2017.00422. eCollection 2017. Review.

3.

The Effect of Chronic Activation of the Novel Endocannabinoid Receptor GPR18 on Myocardial Function and Blood Pressure in Conscious Rats.

Matouk AI, Taye A, El-Moselhy MA, Heeba GH, Abdel-Rahman AA.

J Cardiovasc Pharmacol. 2017 Jan;69(1):23-33. doi: 10.1097/FJC.0000000000000438.

PMID:
27676325
4.

Abnormal cannabidiol attenuates experimental colitis in mice, promotes wound healing and inhibits neutrophil recruitment.

Krohn RM, Parsons SA, Fichna J, Patel KD, Yates RM, Sharkey KA, Storr MA.

J Inflamm (Lond). 2016 Jul 14;13:21. doi: 10.1186/s12950-016-0129-0. eCollection 2016.

5.

Lysophosphatidylinositol Signalling and Metabolic Diseases.

Arifin SA, Falasca M.

Metabolites. 2016 Jan 15;6(1). pii: E6. doi: 10.3390/metabo6010006. Review.

6.

Role of GPR55 during Axon Growth and Target Innervation.

Cherif H, Argaw A, Cécyre B, Bouchard A, Gagnon J, Javadi P, Desgent S, Mackie K, Bouchard JF.

eNeuro. 2015 Nov 9;2(5). pii: ENEURO.0011-15.2015. doi: 10.1523/ENEURO.0011-15.2015. eCollection 2015 Sep-Oct.

7.

Pharmacological profiling of the hemodynamic effects of cannabinoid ligands: a combined in vitro and in vivo approach.

Walsh SK, Hepburn CY, Keown O, Åstrand A, Lindblom A, Ryberg E, Hjorth S, Leslie SJ, Greasley PJ, Wainwright CL.

Pharmacol Res Perspect. 2015 Jun;3(3):e00143. doi: 10.1002/prp2.143. Epub 2015 May 8.

8.

The therapeutic potential of orphan GPCRs, GPR35 and GPR55.

Shore DM, Reggio PH.

Front Pharmacol. 2015 Apr 15;6:69. doi: 10.3389/fphar.2015.00069. eCollection 2015. Review.

9.

The GPR55 agonist lysophosphatidylinositol relaxes rat mesenteric resistance artery and induces Ca(2+) release in rat mesenteric artery endothelial cells.

AlSuleimani YM, Hiley CR.

Br J Pharmacol. 2015 Jun;172(12):3043-57. doi: 10.1111/bph.13107. Epub 2015 Apr 24.

10.

GPR55 deletion in mice leads to age-related ventricular dysfunction and impaired adrenoceptor-mediated inotropic responses.

Walsh SK, Hector EE, Andréasson AC, Jönsson-Rylander AC, Wainwright CL.

PLoS One. 2014 Oct 2;9(9):e108999. doi: 10.1371/journal.pone.0108999. eCollection 2014.

11.

Endothelial atypical cannabinoid receptor: do we have enough evidence?

Bondarenko AI.

Br J Pharmacol. 2014 Dec;171(24):5573-88. doi: 10.1111/bph.12866. Review.

12.

Heteromerization of GPR55 and cannabinoid CB2 receptors modulates signalling.

Balenga NA, Martínez-Pinilla E, Kargl J, Schröder R, Peinhaupt M, Platzer W, Bálint Z, Zamarbide M, Dopeso-Reyes IG, Ricobaraza A, Pérez-Ortiz JM, Kostenis E, Waldhoer M, Heinemann A, Franco R.

Br J Pharmacol. 2014 Dec;171(23):5387-406. doi: 10.1111/bph.12850. Epub 2014 Sep 5.

13.

Novel lysophosphoplipid receptors: their structure and function.

Makide K, Uwamizu A, Shinjo Y, Ishiguro J, Okutani M, Inoue A, Aoki J.

J Lipid Res. 2014 Oct;55(10):1986-95. doi: 10.1194/jlr.R046920. Epub 2014 Jun 2. Review.

14.

Cannabinoid inhibits HIV-1 Tat-stimulated adhesion of human monocyte-like cells to extracellular matrix proteins.

Raborn ES, Jamerson M, Marciano-Cabral F, Cabral GA.

Life Sci. 2014 May 28;104(1-2):15-23. doi: 10.1016/j.lfs.2014.04.008. Epub 2014 Apr 15.

15.

The endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cells.

Wilhelmsen K, Khakpour S, Tran A, Sheehan K, Schumacher M, Xu F, Hellman J.

J Biol Chem. 2014 May 9;289(19):13079-100. doi: 10.1074/jbc.M113.536953. Epub 2014 Mar 18.

16.

The novel endocannabinoid receptor GPR18 is expressed in the rostral ventrolateral medulla and exerts tonic restraining influence on blood pressure.

Penumarti A, Abdel-Rahman AA.

J Pharmacol Exp Ther. 2014 Apr;349(1):29-38. doi: 10.1124/jpet.113.209213. Epub 2014 Jan 15.

17.

Intercellular Lipid Mediators and GPCR Drug Discovery.

Im DS.

Biomol Ther (Seoul). 2013 Nov;21(6):411-22. doi: 10.4062/biomolther.2013.080. Review.

18.

Vascular targets for cannabinoids: animal and human studies.

Stanley C, O'Sullivan SE.

Br J Pharmacol. 2014 Mar;171(6):1361-78. doi: 10.1111/bph.12560. Review.

19.

Modulation of the endocannabinoid system: vulnerability factor and new treatment target for stimulant addiction.

Olière S, Joliette-Riopel A, Potvin S, Jutras-Aswad D.

Front Psychiatry. 2013 Sep 23;4:109. doi: 10.3389/fpsyt.2013.00109. Review.

20.

A role for O-1602 and G protein-coupled receptor GPR55 in the control of colonic motility in mice.

Li K, Fichna J, Schicho R, Saur D, Bashashati M, Mackie K, Li Y, Zimmer A, Göke B, Sharkey KA, Storr M.

Neuropharmacology. 2013 Aug;71:255-63. doi: 10.1016/j.neuropharm.2013.03.029. Epub 2013 Apr 18.

Supplemental Content

Support Center